{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:15:04Z","timestamp":1788077704096,"version":"build-2784847793"},"reference-count":20,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>Background: Fundus diseases are major causes of irreversible visual impairment. Retinal pharmacokinetic behavior may differ between diabetic retinopathy (DR) and age-related macular degeneration (AMD), but disease-specific dosing principles remain insufficiently defined. Objectives: Disease-stratified retinal pharmacokinetic characteristics were evaluated, and a precision drug administration strategy for patients with fundus diseases was developed. Methods: Blood-retinal barrier (BRB) cell models, retinal organoids, retinal pigment epithelium (RPE) models, optical coherence tomography (OCT), serum biomarkers and clinical records were integrated. A retrospective, controlled clinical analysis was performed in patients with DR or AMD, in accordance with ethics approval No. 20240923. Results: DR was characterized by greater barrier permeability and transporter-related retention, whereas AMD was characterized by lipid-associated RPE dysfunction and restricted trans-retinal penetration. The DR model predicted retinal peak concentration with R2 = 0.89, and the AMD model predicted drug half-life with 86% accuracy. Precision administration was associated with reduced injection frequency in DR and AMD and improved anatomical and visual outcomes. Conclusion: Disease-specific retinal pharmacokinetic differences support individualized dosing strategies for fundus diseases. The proposed platform provides a practical framework for precision anti-VEGF therapy and targeted retinal drug delivery.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.9.263.1","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:04:14Z","timestamp":1782633854000},"source":"Crossref","is-referenced-by-count":0,"title":["Study on retinal pharmacokinetic characteristics and precision drug administration strategy in patients with fundus diseases"],"prefix":"10.36721","author":[{"given":"Liang","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Abdelmonem M, Mokaddem AKA and Zakaria YM (2025). TPGS-functionalized nanocarriers with improved flavonoid oral bioavailability and therapeutic action: Pharmacokinetic and mechanistic insights in diabetes-induced retinopathy. Eur. J. Pharm. Biopharm., 216: 114851.","DOI":"10.1016\/j.ejpb.2025.114851"},{"key":"ref1","unstructured":"Chen J (2016). The role of inflammatory factors in diabetic retinopathy. Kunming Medical University, thesis."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Gregori G, Mangoni L, Muzi A, Mogetta V, Gujar R, Chiapponi M, Fruttini D, Dolz-Marco R, Chhablani J and Lupidi M (2025). Vascular perfusion variability in diabetic retinopathy: A sequential interscan optical coherence tomography angiography assessment. J. Clin. Med., 14(7): 2312.","DOI":"10.3390\/jcm14072312"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Guo C, Niu Y, Pan X, Yang J, Li Y, Zhang H and Chen X (2025). Hypoglycemia promotes inner blood-retinal barrier breakdown and retinal vascular leakage in diabetic mice. Sci. Transl. Med., 17(796): eadq5355.","DOI":"10.1126\/scitranslmed.adq5355"},{"key":"ref4","unstructured":"Ji YX, Peng MZ, Ning SQ, Wang Q, Li X and Zhang Y (2025). Study on the distribution of metabolites in diabetic rat retina improved by Panax notoginseng based on mass spectrometry imaging technology. Acta Pharm. Sin., 60(5): 1515-1524."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kadavil H, Adib AS, Marei A, Abdallah AM and Elsaid N (2025). Tyrosine kinase inhibitors and their promising role in treating diabetic retinopathy and other retinal vascular diseases: Overview of routes of administration, pharmacokinetics, formulations and drug delivery applications. Expert Opin. Drug Deliv., 22(9): 1275-1301.","DOI":"10.1080\/17425247.2025.2516668"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Kuo S, Li D, Wargny M, Hadjadj S and Gourdy P (2025). Blood metabolome of cardiovascular disease, diabetic kidney disease and diabetic retinopathy in type 2 diabetes patients: A systematic review and meta-analysis. Endocr. Res., 50: 1-27.","DOI":"10.1080\/07435800.2025.2545832"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Leley SP, Ciulla TA and Bhatwadekar AD (2021). Diabetic retinopathy in the aging population: A perspective of pathogenesis and treatment. Clin. Interv. Aging, 16: 1367-1378.","DOI":"10.2147\/CIA.S297494"},{"key":"ref8","unstructured":"Li M, Mo SW, Li Y, Chen X and Zhang L (2020). Mechanism of blood-retinal barrier injury and therapeutic countermeasures. Int. Eye Sci., 20(11): 1902-1906."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Li M, Yang L, Zhai H, Qiao L, Wang Z, An X and Wang J (2025). A new perspective on protecting the blood-retinal barrier against injury in diabetic retinopathy: Mitophagy. Front. Endocrinol., 16: 1617797.","DOI":"10.3389\/fendo.2025.1617797"},{"key":"ref10","unstructured":"Liu ZQ, Jie CH, Wang JW, Li Y and Huang Q (2022). Research progress on the immune mechanism of diabetic retinopathy. Recent Adv. Ophthalmol., 42(2): 150-154."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Madhusudhan S, Gupta VN, Rahamathulla M, Alqahtani AS and Ahmed MM (2023). Subconjunctival delivery of sorafenib-tosylate-loaded cubosomes for facilitated diabetic retinopathy treatment: Formulation development, evaluation, pharmacokinetic and pharmacodynamic studies. Pharmaceutics, 15(10): 2419.","DOI":"10.3390\/pharmaceutics15102419"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Moccia F and Dragoni S (2025). The calcium signalling profile of the inner blood-retinal barrier in diabetic retinopathy. Cells, 14(12): 856.","DOI":"10.3390\/cells14120856"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Simo R, Ramos H, Ramirez GM, Hernandez C and Garcia-Ramirez M (2025). Effect of sitagliptin on diabetes-induced hyperpermeability of blood-retinal barrier components. Eye, 39(12): 1-2.","DOI":"10.1038\/s41433-025-03924-w"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Teng-Teng Y, Yuan Y, Xiao-Liang J, Xue-Li C and Lei W (2020). Intraocular pharmacokinetics of anti-vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil-filled eyes of proliferative diabetic retinopathy: A randomized controlled pilot study. Acta Ophthalmol., 98(7): e795-e800.","DOI":"10.1111\/aos.14386"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Wang N, Yao F, Xu W, Li Y, Chen X and Zhang L (2025). The transcription factor Islet-1 regulates diabetes-induced inner blood-retinal barrier disruption. Invest. Ophthalmol. Vis. Sci., 66(13): 8.","DOI":"10.1167\/iovs.66.13.8"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Yucheng W, Beibei X, Xiaoli W, Hong L and Jun Z (2021). Pharmacokinetic study of Tangwang Mingmu granule for the management of diabetic retinopathy based on network pharmacology. Pharm. Biol., 59(1): 1334-1350.","DOI":"10.1080\/13880209.2021.1979051"},{"key":"ref17","unstructured":"Zhang HW and Shi Y (2021). Research progress on diabetic retinopathy and blood-retinal barrier injury mechanism. Chin. Arch. Tradit. Chin. Med., 39(3): 105-109."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Zhang J, Chang K, Shangguan Y, Li X and Wang H (2025b). Flotillin-1 ameliorates experimental diabetic retinopathy by inhibiting ferroptosis in blood-retinal barrier. J. Mol. Med., 103(6): 1-15.","DOI":"10.1007\/s00109-025-02544-x"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhang S, Li Y, Wang N and Xu W (2025a). Dectin-1 drives diabetic retinopathy via inducing microglia-mediated inflammation and blood-retinal barrier breakdown. Dev. Neurobiol., 85(4): e22997.","DOI":"10.1002\/dneu.22997"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:03:08Z","timestamp":1788076988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pjps.pk\/single-article?id=7868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.9.263.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}